PDCD1 and colonic neoplasm: Despite employing regorafenib or anti-PD-1 antibody as third-line treatment in advanced colon cancer therapy, no robust and durable clinical responses were documented when used as single agents in proficient mismatch repair (pMMR)/microsatellite stable (MSS)-colorectal cancer.